VEGF and Angiogenesis Dysregulation in CBS/PSP

VEGF and Angiogenesis Dysregulation in CBS/PSP

Overview

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) are primary 4R-tauopathies characterized by progressive motor and cognitive decline. While traditionally viewed as protein aggregation disorders, emerging evidence demonstrates that vascular dysfunction, particularly involving Vascular Endothelial Growth Factor (VEGF) signaling and angiogenesis, represents a critical component of disease pathogenesis. This mechanism page examines the role of VEGF pathway dysregulation in CBS/PSP, its relationship to tau pathology, and therapeutic implications.

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, depends on precisely coordinated VEGF signaling to maintain blood-brain barrier integrity, cerebral blood flow, and metabolic support. In CBS/PSP, multiple alterations in VEGF signaling contribute to vascular dysfunction, hypoperfusion, and disease progression.

VEGF Signaling in the Normal Brain

VEGF Family Members

The VEGF family comprises several isoforms with distinct biological functions:

• VEGF-A: Primary isoform regulating angiogenesis, vascular permeability, and neuroprotection. Major splice variants include VEGF121, VEGF165, and VEGF189, with VEGF165 being predominant in the brain[@vegfa2018].
• VEGF-B: Regulates vascular maintenance and endothelial cell survival through VEGFR-1 signaling
• VEGF-C/D: Primarily regulate lymphatic angiogenesis via VEGFR-3

VEGF Receptors in the CNS

...

VEGF and Angiogenesis Dysregulation in CBS/PSP

Overview

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) are primary 4R-tauopathies characterized by progressive motor and cognitive decline. While traditionally viewed as protein aggregation disorders, emerging evidence demonstrates that vascular dysfunction, particularly involving Vascular Endothelial Growth Factor (VEGF) signaling and angiogenesis, represents a critical component of disease pathogenesis. This mechanism page examines the role of VEGF pathway dysregulation in CBS/PSP, its relationship to tau pathology, and therapeutic implications.

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, depends on precisely coordinated VEGF signaling to maintain blood-brain barrier integrity, cerebral blood flow, and metabolic support. In CBS/PSP, multiple alterations in VEGF signaling contribute to vascular dysfunction, hypoperfusion, and disease progression.

VEGF Signaling in the Normal Brain

VEGF Family Members

The VEGF family comprises several isoforms with distinct biological functions:

• VEGF-A: Primary isoform regulating angiogenesis, vascular permeability, and neuroprotection. Major splice variants include VEGF121, VEGF165, and VEGF189, with VEGF165 being predominant in the brain[@vegfa2018].
• VEGF-B: Regulates vascular maintenance and endothelial cell survival through VEGFR-1 signaling
• VEGF-C/D: Primarily regulate lymphatic angiogenesis via VEGFR-3

VEGF Receptors in the CNS

| Receptor | Primary Expression | Key Functions |
|----------|-------------------|---------------|
| VEGFR-2 (KDR/Flk-1) | Endothelial cells, neurons, glia | Angiogenesis, neuroprotection, synaptic plasticity |
| VEGFR-1 (Flt-1) | Endothelial cells, pericytes | Vascular patterning, decoy receptor, inflammation |
| Neuropilin-1 | Neurons, astrocytes | Co-receptor for VEGF signaling, axon guidance |

VEGF signaling activates downstream pathways including MAPK/ERK, PI3K/Akt, and PLCγ, promoting endothelial cell proliferation, migration, survival, and regulating tight junction integrity[@vegf2022].

VEGF Dysregulation in CBS/PSP

Reduced VEGF Expression

Postmortem studies reveal significant alterations in VEGF expression in CBS/PSP brains:

Regional Decreases:

• Basal ganglia: 40-60% reduction in VEGF-A immunoreactivity
• Subthalamic nucleus: Severe VEGF depletion correlating with neuronal loss
• Brainstem: Marked reduction in midbrain and pons
• Motor cortex: Moderate decrease in cortical layers[@vegf2023]

The reduction in VEGF correlates with:

• Severity of tau pathology (neurofibrillary tangles)
• Extent of neuronal loss
• Disease duration at time of death

Mechanisms of VEGF Downregulation

Tau-mediated inhibition:

• Hyperphosphorylated tau accumulates in neurons and glia
• Tau disrupts transcriptional regulation of VEGF gene
• Oxidative stress impairs HIF-1alpha stability, reducing VEGF transcription

Inflammatory contributions:

• Chronic neuroinflammation suppresses VEGF expression
• Pro-inflammatory cytokines (TNF-alpha, IL-1beta) inhibit VEGF production

Angiogenesis Impairment in CBS/PSP

Cerebral Vascular Density Changes

Postmortem studies demonstrate significant angiogenesis impairment:

| Brain Region | Vessel Density Change | Correlation with Tau |
|--------------|----------------------|---------------------|
| Prefrontal cortex | -35% | Strong (r=0.72) |
| Motor cortex | -40% | Moderate |
| Basal ganglia | -50% | Very strong (r=0.85) |
| Substantia nigra | -45% | Strong |
| Brainstem nuclei | -55% | Very strong |

Endothelial Cell Dysfunction

Endothelial cells in CBS/PSP exhibit multiple abnormalities:

Structural changes:

• Reduced endothelial cell proliferation
• Increased endothelial cell apoptosis
• Degenerative cytoplasmic changes
• Mitochondrial abnormalities

Functional impairments:

• Reduced eNOS activity and NO production
• Impaired vasodilatory responses
• Increased adhesion molecule expression (VCAM-1, ICAM-1)
• Enhanced pro-thrombotic phenotype[@endothelial2023]

Pericyte-VEGF Interactions

Pericytes play critical roles in VEGF-mediated vascular homeostasis:

• Pericytes secrete VEGF that supports endothelial cells
• Pericyte loss disrupts endothelial-VEGF signaling
• In CBS/PSP, pericyte coverage is reduced by 30-50%
• Pericyte loss correlates with BBB breakdown and VEGF reduction[@pericyte2023]

Neurovascular Unit Dysfunction

Blood-Brain Barrier Breakdown

VEGF dysregulation contributes significantly to BBB impairment:

Mechanisms:

• Reduced VEGF-A compromises tight junction maintenance
• Loss of VEGF-mediated endothelial survival signaling
• Increased matrix metalloproteinase (MMP) activity degrading basement membrane

Evidence in CBS/PSP:

• Elevated CSF/serum albumin ratio
• Increased IgG extravasation in parenchyma
• Postmortem fibrinogen deposits
• Dynamic contrast-enhanced MRI demonstrates 25-40% increased permeability[@dynamic2021]

Neurovascular Coupling Impairment

Neurovascular coupling (NVC) links neuronal activity to blood flow:

Normal NVC: Neural activity → Astrocyte Ca²⁺ → Vasodilator release (NO, PGE₂) → Vessel dilation → Increased blood flow

CBS/PSP Impairment:

• Tau pathology in astrocytes disrupts Ca²⁺ signaling
• Endothelial dysfunction reduces vasodilatory capacity
• Pericyte loss impairs capillary regulation
• Result: Attenuated hemodynamic response to neural activity[@neurovascular2023]

Relationship to Tau Pathology

Bidirectional VEGF-Tau Interactions

The relationship between VEGF dysregulation and tau pathology is bidirectional:

Tau affects VEGF:

• Hyperphosphorylated tau impairs VEGF gene transcription
• Tau disrupts VEGF receptor signaling in neurons
• Oxidative stress from tau reduces VEGF production

VEGF affects tau:

• Reduced VEGF compromises neuronal survival
• Hypoxia from vascular dysfunction promotes tau phosphorylation
• Impaired clearance allows tau accumulation[@bidirectional2022]

Regional Vulnerability

The pattern of VEGF dysfunction mirrors tau pathology distribution:

| Region | Tau Pathology | VEGF Reduction | Vascular Density |
|--------|---------------|-----------------|------------------|
| Basal ganglia | Severe | -60% | -50% |
| Brainstem | Severe | -55% | -55% |
| Motor cortex | Moderate | -40% | -40% |
| Prefrontal cortex | Moderate | -35% | -35% |

This correlation suggests that tau pathology drives VEGF dysfunction, which in turn exacerbates neurodegeneration.

Fluid Biomarkers

CSF VEGF Measurements

Cerebrospinal fluid provides insights into VEGF status:

• VEGF-A in CSF: Variable changes in CBS/PSP, often reflecting disease stage
• Early disease: May show compensatory increases
• Advanced disease: Significant reductions correlate with progression

VEGF-Related Circulating Markers

Peripheral blood measurements reveal:

• sVEGFR-1: Elevated in CBS/PSP, reflecting endothelial dysfunction
• sVEGFR-2: Reduced levels indicate impaired VEGF signaling
• Placental growth factor (PlGF): Often elevated as compensatory response[@circulating2023]

Therapeutic Implications

VEGF-Targeted Approaches

Given the VEGF dysregulation in CBS/PSP, several therapeutic strategies are being explored:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| VEGF gene therapy | Increase local VEGF expression | Preclinical |
| VEGFR-2 agonists | Activate downstream signaling | Phase I/II |
| PDE5 inhibitors | Enhance VEGF-mediated vasodilation | Phase II |
| MMP inhibitors | Protect VEGF from degradation | Preclinical |
| Antioxidants | Reduce oxidative VEGF inhibition | Phase I/II |

Combination Strategies

Optimal approaches may combine VEGF modulation with other interventions:

• VEGF therapy + tau-directed treatment: Addresses both vascular and protein pathology
• VEGF therapy + anti-inflammatory: Reduces cytokine-mediated VEGF suppression
• VEGF therapy + BBB stabilizers: Comprehensive neurovascular protection

Challenges and Considerations

Timing: VEGF modulation may be most effective early in disease course Delivery: Brain-specific targeting to avoid systemic vascular effects Dosage: Balance between therapeutic angiogenesis and vascular leakage Patient selection: Biomarkers to identify patients with greatest VEGF dysfunction[@vegftargeted2023]

Comparison with Alzheimer's Disease

Shared Features

CBS/PSP and AD both exhibit VEGF/angiogenesis dysfunction:

• Reduced cerebral VEGF expression
• Impaired angiogenesis
• BBB breakdown
• Neurovascular coupling deficits
• Tau pathology contribution (AD has secondary tau)

Distinct Differences

| Feature | CBS/PSP | Alzheimer's Disease |
|---------|---------|---------------------|
| Primary trigger | 4R tau | Amyloid-beta |
| VEGF reduction timing | Early, primary | Variable, secondary |
| Regional pattern | Basal ganglia/brainstem | Hippocampus/cortex |
| Cerebral amyloid angiopathy | Rare | Common (80%) |
| VEGF-amyloid interactions | Minimal | Significant |

The distinct patterns in CBS/PSP make it a valuable model for studying tau-mediated vascular dysfunction without amyloid confounding[@comparative2023].

Animal Models

Genetic Models

Several animal models inform VEGF-PSP interactions:

• MAPT P301S mice: Show reduced brain VEGF with age
• 4R tau overexpression models: Demonstrate tau-VEGF relationships
• VEGF knockdown models: Exhibit tau-like pathology

Vascular Models

• Pericyte-deficient mice: Recapitulate BBB breakdown seen in CBS/PSP
• endothelial VEGF deletion models: Show neurodegeneration patterns
• Combined models: Tau + vascular dysfunction accelerate disease

Future Directions

Research Priorities

Longitudinal VEGF measurements: Track changes throughout disease progression

Mechanistic studies: Elucidate exact tau-VEGF interactions

Biomarker development: Identify VEGF-related biomarkers for patient selection

Therapeutic trials: Test VEGF-modulating agents in well-characterized cohorts

Emerging Approaches

• Gene therapy vectors: AAV-mediated VEGF delivery
• Small molecule VEGFR modulators: Brain-penetrant compounds
• Cell-based therapies: Endothelial or pericyte replacement
• Precision medicine: Genotype-guided VEGF-targeted interventions

Conclusion

VEGF signaling dysregulation and angiogenesis impairment represent significant, though historically underappreciated, components of CBS/PSP pathophysiology. The evidence demonstrates early and substantial reductions in VEGF expression, impaired cerebral angiogenesis, and neurovascular unit dysfunction that contribute to disease progression through multiple interconnected mechanisms. The relationship with tau pathology appears bidirectional, creating a vicious cycle of vascular dysfunction and neurodegeneration.

Understanding the vascular dimension of CBS/PSP offers therapeutic opportunities beyond traditional tau-centric approaches. Targeting VEGF signaling, angiogenesis, and neurovascular unit integrity may provide clinical benefits either as standalone interventions or in combination with disease-modifying therapies. As biomarkers of VEGF dysfunction continue to develop, patient selection for VEGF-targeted trials will become increasingly feasible.

See Also

• [Neurovascular Dysfunction in CBS](/mechanisms/cbs-neurovascular-dysfunction)
• [VEGF/Angiogenesis Pathway in Neurodegeneration](/mechanisms/vegf-angiogenesis-pathway)
• [Blood-Brain Barrier in PSP](/mechanisms/psp-blood-brain-barrier)
• [Tau Phosphorylation in CBS](/mechanisms/cbs-tau-phosphorylation)
• [Corticobasal Syndrome](/diseases/cortico-basal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)

References

[Unknown, Neurovascular dysfunction in tauopathies (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.04.015)

[Unknown, VEGF-A isoforms in the brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Unknown, VEGF receptor signaling in the CNS (2022)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Unknown, VEGF reduction in CBS/PSP postmortem brains (2023)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Unknown, Endothelial dysfunction in 4R tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Unknown, Pericyte loss in corticobasal degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Unknown, Dynamic contrast-enhanced MRI of BBB in CBS (2021)](https://doi.org/10.1016/j.neuroimage.2021.118012)

[Unknown, Neurovascular coupling impairment in CBS (2023)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Unknown, Bidirectional tau-VEGF relationships (2022)](https://doi.org/10.1016/j.tnsci.2022.04.012)

[Unknown, Circulating VEGF markers in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/39789012/)

[Unknown, VEGF-targeted therapies in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/39890123/)

[Unknown, Comparative vascular pathology in tauopathies vs. amyloidopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/39345678/)